## Satoshi Soen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2852380/publications.pdf

Version: 2024-02-01

51 papers 2,692 citations

331538 21 h-index 50 g-index

78 all docs

78 docs citations

78 times ranked 2570 citing authors

#	Article	IF	CITATIONS
1	Diagnostic criteria for primary osteoporosis: year 2000 revision. Journal of Bone and Mineral Metabolism, 2001, 19, 331-337.	1.3	424
2	Japanese 2011 guidelines for prevention and treatment of osteoporosisâ€"executive summary. Archives of Osteoporosis, 2012, 7, 3-20.	1.0	284
3	Diagnostic criteria for primary osteoporosis: year 2012 revision. Journal of Bone and Mineral Metabolism, 2013, 31, 247-257.	1.3	251
4	Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. Journal of Bone and Mineral Metabolism, 2010, 28, 365-383.	1.3	237
5	Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Journal of Bone and Mineral Metabolism, 2017, 35, 6-19.	1.3	212
6	Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. Journal of Bone and Mineral Metabolism, 2014, 32, 337-350.	1.3	176
7	Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). Journal of Bone and Mineral Metabolism, 2005, 23, 105-109.	1.3	159
8	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq0 0 0 r	rgBT/Over	lock 10 Tf 50 4
9	2019, 78, 899-907.  Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone, 2018, 116, 58-66.	1.4	65
10	Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 2018, 67, 1042-1051.	6.1	63
11	Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial.  Arthritis Research and Therapy, 2014, 16, R18.	1.6	60
12	Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Modern Rheumatology, 2013, 23, 430-439.	0.9	56
13	Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. Modern Rheumatology, 2014, 24, 410-418.	0.9	49
14	Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan. Digestion, 2011, 83, 108-123.	1.2	44
15	Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Current Medical Research and Opinion, 2016, 32, 1261-1268.	0.9	41
16	Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. Journal of Orthopaedic Science, 2011, 16, 778-784.	0.5	30
17	Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. Journal of Gastroenterology, 2012, 47. 540-552.	2.3	30
18	Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Current Medical Research and Opinion, 2017, 33, 2049-2056.	0.9	30

#	Article	lF	CITATIONS
19	Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Modern Rheumatology, 2013, 23, 430-439.	0.9	30
20	A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporosis International, 2021, 32, 2301-2311.	1.3	24
21	Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group. Calcified Tissue International, 2015, 97, 542-550.	1.5	21
22	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). Journal of Bone and Mineral Metabolism, 2020, 38, 522-532.	1.3	20
23	Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies. Calcified Tissue International, 2019, 104, 193-200.	1.5	15
24	Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Journal of Bone and Mineral Metabolism, 2019, 37, 886-892.	1.3	14
25	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Modern Rheumatology, 2021, 31, 34-41.	0.9	14
26	Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. Journal of Bone and Mineral Metabolism, 2020, 38, 141-144.	1.3	12
27	Justification criteria for vertebral fractures: year 2012 revision. Journal of Bone and Mineral Metabolism, 2013, 31, 258-261.	1.3	11
28	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. Journal of Rheumatology, 2021, 48, 1663-1671.	1.0	10
29	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	0.9	9
30	Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis. Current Medical Research and Opinion, 2015, 31, 1771-1779.	0.9	9
31	Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan. Journal of Bone and Mineral Metabolism, 2019, 37, 273-281.	1.3	9
32	Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. Journal of Bone and Mineral Metabolism, 2021, 39, 446-455.	1.3	9
33	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open, 2020, 6, e001249.	1.8	8
34	Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Journal of Bone and Mineral Metabolism, 2019, 37, 491-495.	1.3	7
35	Family caregiver burden of patients with osteoporotic fracture in Japan. Journal of Bone and Mineral Metabolism, 2021, 39, 612-622.	1.3	6
36	Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. Journal of Bone and Mineral Metabolism, 2021, 39, 1019-1030.	1.3	6

#	Article	lF	CITATIONS
37	Different changes in the biomarker C-terminal telopeptides of type II collagen (CTX-II) following intra-articular injection of high molecular weight hyaluronic acid and oral non-steroidal anti-inflammatory drugs in patients with knee osteoarthritis: a multi-center randomized controlled study. Osteoarthritis and Cartilage, 2022, 30, 852-861.	0.6	6
38	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	0.9	5
39	A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporosis and Sarcopenia, 2020, 6, 191-198.	0.7	4
40	Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5Âmg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice. Journal of Bone and Mineral Metabolism, 2017, 35, 419-427.	1.3	3
41	Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Current Medical Research and Opinion, 2020, 36, 1847-1859.	0.9	3
42	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism, 2020, 38, 511-521.	1.3	3
43	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. PLoS ONE, 2021, 16, e0253547.	1.1	3
44	Fracture risk associated with glucocorticoid-induced osteoporosis in Japan. Journal of Bone and Mineral Metabolism, 2022, 40, 636-647.	1.3	3
45	Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05. Archives of Osteoporosis, 2022, 17, 7.	1.0	2
46	Cost-Effectiveness Analysis of Celecoxib in the Treatment of Patients with Chronic Pain in Japan. Iryo To Shakai, 2014, 24, 289-302.	0.0	1
47	Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis. Journal of Bone and Mineral Metabolism, 2020, 38, 86-98.	1.3	1
48	A case of early rheumatoid arthritis with rapid bilateral destruction of the hip joints. Modern Rheumatology Case Reports, 2018, 2, 5-8.	0.3	0
49	AB0291D PREDICTORS OF NEW BONE EROSION IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CSDMARDS: ANALYSIS OF DATA FROM THE DRIVE AND DESIRABLE STUDIES. , 2019, , .		0
50	The latest findings about the drug therapy of osteoporosis. Nihon Koku Geka Gakkai Zasshi, 2020, 66, 40-51.	0.0	0
51	Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. Modern Rheumatology, 2021, , .	0.9	0